Methods: A multi-center retrospective cohort study of adult patients (aged ≥ 18 years) admitted to 140 US hospitals with pneumonia and/or sepsis from 2010–2015, included in the Premier Research database. Patients with community-onset infection, antibiotic treatment beginning within the first 2 hospital days, and continued for at least 3 consecutive days were included. Patients were excluded if they had been transferred from another acute care facility, had cystic fibrosis, had a hospital length of stay of 1 day or less, co-existent urinary tract infection, gastrointestinal/ intra-abdominal infection, or simultaneous presence of other CAP pathogens. Pneumonia and sepsis were identified by ICD-9 codes.
Results: 13,165 patients met the inclusion criteria, of which 1247 had E.Coli CAP. Majority of patients with E-CAP were non-nursing home residents (90.2%, 1125/1247). 69.3% (864/1247) patients with E-CAP presented with ‘sepsis syndrome’ compared to only 48.1 % in other gram negative-CAP and 62.5 % in P-CAP. Aspiration pneumonia was diagnosed in 5.9% (73/1247) with E-CAP. Blood cultures were positive in 59.9 % (748/1247) of patients with E-CAP with 84.8% positivity in patients with sepsis syndrome. Patients with E-CAP compared to P-CAP were more likely to require ICU-level care (42.6% vs. 38.2 %), mechanical ventilation (19.3% vs. 15.7%), and require vasopressors (21% vs. 13.8%). In-hospital mortality was 14.8% in E-CAP compared to 7.4% in P-CAP. The median cost of hospitalization was great in E-CAP than P-CAP ($ 12,420.1 vs. $ 9857.5 ) Re-admission within 30 days was greater among patients with E-CAP than P-CAP (5.4% vs. 4%). 36.8 % of isolates were resistant to fluoroquinolones, 10.4% to ceftriaxone and 18.1% to aminoglycosides. Only 10/1247(0.8%) were multi-drug resistant.
Conclusion: E.coli is an important cause of severe CAP, with higher mortality, greater need for ICU-level care, and higher re-admission rates than patients with pneumococcal pneumonia. The rate of fluoroquinolone resistance was high and empiric quinolones should be used with caution for patients who are critically ill due to E-CAP
T. M. John,
S. Haessler, None
K. Brizendine, None
P. C. Yu, None
P. Imrey, None
M. B. Rothberg, None